BG
ADMA icon

Bellevue Group’s ADMA Biologics ADMA Stock Holding History

Bellevue Group’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-16,900
Closed -$308K – 150
2025
Q2 		$308K Hold
16,900
– – 0.01% 115
2025
Q1 		$335K Hold
16,900
– – 0.01% 126
2024
Q4 		$290K Sell
16,900
-9,000
-35% -$169K 0.01% 136
2024
Q3 		$518K Sell
25,900
-5,000
-16% -$77.8K 0.01% 128
2024
Q2 		$345K Sell
30,900
-10,000
-24% -$83.9K 0.01% 135
2024
Q1 		$270K Buy
+40,900
New +$224K ﹤0.01% 148

Other funds holding ADMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
SHCM
Sachem Head Capital Management New York $4.82B AUM 73.38% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Bellevue Group's ADMA Position: Q3 2025 in Review

Bellevue Group sold out of ADMA Biologics (ADMA) in Q3 2025, closing a stake of 16,900 shares — an estimated $308K sold.

Bellevue Group first reported a position in ADMA in Q1 2024 and held it in 6 quarters. The position peaked at $518K in Q3 2024. 365 funds tracked by Wall St. Rank hold ADMA as of Q3 2025.

  • Bellevue Group reported no remaining ADMA Biologics position as of Q3 2025 after selling out during the quarter.
  • Bellevue Group sold 16,900 ADMA Biologics shares in Q3 2025, an estimated $308K.
  • Bellevue Group first reported a position in ADMA Biologics in Q1 2024 and held it in 6 quarters.
  • Bellevue Group's ADMA Biologics position peaked at $518K in Q3 2024.
  • 365 funds tracked by Wall St. Rank held ADMA Biologics as of Q3 2025.

Based on Bellevue Group's 13F filing for Q3 2025, filed 14 Nov 2025.